FDA reviews GSK's response to Complete Response letter for Horizant
Links shared publicly online about this topic.
- 742total visits
FDA reviews GSK's response to Complete Response letter for Horizant
View full resource at news-medical.net
Tags: Parkinson's Disease, Disease and Condition, Diet and Nutrition, Drug, FDA, GlaxoSmithKline, disease
Most Recently Shared on November 8, 2010 at 11:32 am By:
Parkinson's Disease: FDA reviews GSK's response to Complete Response letter for Horizant: GlaxoSmithKline and Xe... http://bit.ly/c20jt2
FDA accepts to review GSK's response to Complete Response letter for Horizant
news-medical.net — “GlaxoSmithKline and XenoPort, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review GSK's response to FDA's Complete Response letter for Horizant (gabapentin enacarbil) Extended-Release Tablets. Horizant is under review for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).” View full resource at news-medical.net
Most Recently Shared on November 8, 2010 at 7:28 am By:
FDA accepts to review GSK's response to Complete Response letter for Horizant: GlaxoSmithKline and XenoPort, Inc... http://bit.ly/boZuNV
GlaxoSmithKline And XenoPort Receive FDA Complete Response Letter For Horizant™ (GSK1838262/XP13512) For RLS
medicalnewstoday.com — “GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA” View full resource at medicalnewstoday.com
Most Recently Shared on February 20, 2010 at 3:08 pm By:
GlaxoSmithKline And XenoPort Receive FDA Complete Response Letter For Horizant™ (GSK1838262/XP13512) For RLS http://mnt.to/3xV4 #sleep
GlaxoSmithKline And XenoPort Receive FDA Complete Response Letter For Horizant™ (GSK1838262/XP13512) For RLS
medicalnewstoday.com — “GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA)” View full resource at medicalnewstoday.com
Most Recently Shared on February 18, 2010 at 11:37 pm By:
GlaxoSmithKline And XenoPort Receive FDA Complete Response Letter For Horizantâ„¢ (GSK1838262/XP13512) For RLS GlaxoS.. http://bit.ly/aT7fAy
Advertisement
